Government amends Drug Rules to crack down on pharmaceutical companies submitting fraudulent documents
New Delhi: To make India's drug regulatory system more transparent and reliable, the Union Ministry of Health and Family Welfare has made significant amendments to the Drug Rules, 1945. Under the new rules, if a company or organization submits false or fabricated documents or scientific data while applying for a drug license, its application will not only be rejected but it will also be barred from filing a new application for a specified period.
The government has notified this amendment through GSR 756(E) (October 16, 2025). This provision will apply to all license and approval applications filed under the Drug Rules, 1945.
Previously, submitting false information resulted in rejection of the application or cancellation of the existing license. Following the amended rules, the company or organization will not be permitted to file a new application with the state or central regulatory authority for a specified period. However, before such action is taken, a show-cause notice will be issued, providing the relevant parties with an opportunity to present their case. A provision for appeal has also been made.
According to the Ministry of Health, the quality, safety, and efficacy of drugs are assessed based on scientific and proven data. Falsified documents or inaccurate data not only impact the credibility of the regulatory process but also pose a serious threat to public health.
The government states that this amendment will strengthen India's drug regulatory system in line with global standards, encourage honest drug manufacturers, and ensure effective action against violators.
